What is Zacks Research’s Estimate for PBH FY2025 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Stock analysts at Zacks Research raised their FY2025 earnings per share estimates for Prestige Consumer Healthcare in a report released on Tuesday, January 14th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.51 for the year, up from their previous forecast of $4.43. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q1 2026 earnings at $1.02 EPS, Q4 2026 earnings at $1.30 EPS, Q1 2027 earnings at $1.12 EPS, Q2 2027 earnings at $1.24 EPS and FY2027 earnings at $4.98 EPS.

Other research analysts have also recently issued reports about the company. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. StockNews.com downgraded Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Thursday. Jefferies Financial Group restated a “hold” rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Finally, DA Davidson reiterated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Hold” and an average price target of $85.25.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $78.58 on Thursday. The company’s 50 day moving average price is $80.52 and its two-hundred day moving average price is $74.49. The firm has a market capitalization of $3.88 billion, a P/E ratio of 19.12, a P/E/G ratio of 2.08 and a beta of 0.51. Prestige Consumer Healthcare has a fifty-two week low of $58.22 and a fifty-two week high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same period last year, the company posted $1.07 EPS.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the sale, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock worth $3,187,300 over the last ninety days. 1.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC increased its stake in shares of Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after acquiring an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares during the period. nVerses Capital LLC increased its stake in Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank raised its holdings in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the period. Finally, International Assets Investment Management LLC boosted its position in shares of Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after purchasing an additional 1,138 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.